Nitrosative status in benign epithelial cystic ovarian tumors of nonendometrioid origin




nitrosative status, cystic ovarian tumors of nonendometrioid origin, NOx, iNOS, immunohistochemistry


Ovarian tumors are in second place (6–8%) from of all the female genital tumors. Benign forms are found in 75–80% of true ovarian tumors. Despite the fairly detailed knowledge of ovarian tumors, causes of origin and benign tumors of ovarian cysts remain open. Several studies have shown the important role of NO in ovarian physiology. It was shown that NO is synthesized locally ovaries and may play a role in the development of follicles, ovulation and luteal formation. Data on changes in the content NO derived and NOS activity in benign ovarian tumor are absent.

The aim of the study was to investigate the characteristics of nitrosative status of benign epithelial cystic ovarian tumors of nonendometrioid origin. 220 patients of reproductive age were examined: 40 patients with ovarian follicular cysts, 60 – with serous cystadenomas, 60 – with mucinous cystadenomas, 30 – with cystadenocarcinomas of nonendometrioidnogo origin, 30 patients consist control group. NOx level of in the serum and in intracystic content, iNOS imunoreactivity in the walls of the remote masses were investigated.

Study of NOx levels in biological fluids revealed the likely reduction of serum neutral NO metabolites in the cystadenocarcinomas, serous and mucinous cystadenomas in comparison with follicular cysts and control. Differences of intracystic NOx concentrations in mucinous, serous cystadenomas and follicular cysts was small.

Immunohistochemical study of iNOS expression showed its small level in follicular cysts and benign cystadenomas, but high level in cystadenocarcinomas.

Thus, NO and iNOS effect of on hyperproliferation processes in the ovaries is twofold. NO and iNOS reducing expression and their minor activity may impact on the cystic tumor formation and benign tumor formation in the ovaries. NO overexpression and iNOS increased activity associated with the malignancy processes in cystic formations of epithelial origin.

Author Biographies

M. A. Lysenko, Odesa National Medical University; University Hospital ONMedU

Postgraduate student of the Obstetrics and Gynecology Department № 1; Doctor at Surgical Department of minimally invasive methods of diagnosis and treatment

V. G. Dubinina, Odesa National Medical University

MD, professor, head of the Oncology Department with a course of radiation diagnosis, therapy and radiation medicine

О. М. Nosenko, Odesa National Medical University

MD, professor, Obstetrics and Gynecology Department № 1


  1. Activation of lipid peroxidation as a leading pathogenetic factor of typical pathological processes and diseases of different etiologies [Online]. Publishing “Academy of Natural Science” (2012). Avialable from: [], last accessed Feb 25, 2016.
  2. Dubinina, V.G., Rybin, A.I., Kuznetsova, O.V. “Sanogenesis in patients with the platynorefractory ovarian cancer.” Journal of Maritime Medicine 1.2 (2014): 51–57.
  3. Kakurina, G.V. Nitric oxide role of in the regulation of apoptosis and proliferation in tumor cells. Thesis abstract for the PhD degree, specializations 14.00.14, 14.00.16. Tomsk (2004): 19 p.
  4. Komarevtseva, I.A., Orlova, E.A., Tarasova, M.V., et al. “Nitric oxide level in tissues, serum, mononuclear and mesenchymal stem cells.” Ukrainian Journal of Clinical and Laboratory Medicine 4.4 (2009): 133–137.
  5. Markers of inflammation and oxidative stress [Online]. Avialable from: [ uf/59e/59e74cd08ad31f9c72ede 8466c1b211a.pdf], last accessed Feb 25, 2016.
  6. Metelskaya, V.A., Gumanova, N.G. “Screening method for determining the nitric oxide level in serum metabolites.” Clinical Laboratory Diagnostics 6 (2005): 15–18.
  7. Nosenko, O.M. Benign ovary cystic formation: epidemiology, pathogenesis, diagnosis and recovery of reproductive health. Thesis abstract for the MD degree, specialization 14.01.01. Kyiv (2008): 42 p.
  8. Raevskaya, T.A. Nitric oxide donors as modulators of tumors drug resistance. Thesis abstract for the PhD degree, specialization 03.00.02. Chernogolovka (2006): 123 p.
  9. Serebrennikova, K.G., Kuznetsova, E.P. “Current concepts of etiology and pathogenesis of tumor-like formations and benign ovarian tumors.” Saratov Journal of Medical Science 6.3 (2010): 552–8.
  10. Akaike, T., Maeda, H. “Nitric oxide and virus infection.” Immunology 101.3 (2000): 300–8.
  11. Andrade, S.P., Hart, I.R., Piper, P.J. “Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature.” British Journal of Pharmacology 107.4 (1992): 1092–5.
  12. Chhatwal, V.J.S., Moochhala, S.M., Chan, S.T.F., Ngoi, S.S. “Nitric oxide and cancer.” Medical Hypotheses 46.1 (1996): 21–4.
  13. Chu, S.C., Marks-Konczalik, J., Wu, H.-P., Banks, T.C., Moss, J. “Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters.” Biochemical and Biophysical Research Communications 248.3 (1998): 871–8.
  14. Furchgott, R.F. “An historical survey and prospects of research on EDRF.” Nihon Heikatsukin Gakkai Zasshi 23.6 (1987): 435–40.
  15. Nomelini, R.S., de Abreu Ribeiro, L.C., Tavares-Murta, B.M., et al. “Production of Nitric Oxide and Expression of Inducible Nitric Oxide Synthase in Ovarian Cystic Tumors.” Mediators Inflamm (2008). DOI: 10.1155/2008/186584
  16. Ohshima, H., Bartsch, H. “Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis.” Mutation Research / Fundamental and Molecular Mechanisms of Mutagenesis 305.2 (1994): 253–64.
  17. Özel, E., Peştereli, H.E., Şimşek, T., Erdoğan, G., Karaveli, F.Ş. “Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?” International Journal of Gynecological Cancer 16.2 (2006): 549–55.
  18. Reis, F.M., Faletti, A., Luisi, S., Bifulco, G., et al. “High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites.” Mol Hum Reprod 6.12 (2000): 1079–83.
  19. Rieder, J., Marth, C., Totzke, G., Smolny, M., et al. “Different patterns of inducible nitric oxide synthase gene expression in ovarian carcinoma cell lines.” Anticancer Research 20.5 (2000): 3251–8.
  20. Shi, Q., Xiong, Q., Wang, B., Le, X., Khan, N.A., Xie, K. “Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis.” Cancer Research 60.10 (2000): 2579–83.
  21. Yang, G.Y., Taboada, S., Liao, J. “Induced nitric oxide synthase as a major player in the oncogenic transformation of inflamed tissue.” Methods Mol Biol 512 (2009): 119–56. DOI: 10.1007/978-1-60327-530-9_8




How to Cite

Lysenko, M. A., Dubinina, V. G., & Nosenko О. М. (2016). Nitrosative status in benign epithelial cystic ovarian tumors of nonendometrioid origin. REPRODUCTIVE ENDOCRINOLOGY, (27), 78–82.



Tumors and pretumoral pathology